{"id":"NCT04773587","sponsor":"Arcutis Biotherapeutics, Inc.","briefTitle":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","officialTitle":"A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-27","primaryCompletion":"2022-08-30","completion":"2022-08-30","firstPosted":"2021-02-26","resultsPosted":"2024-10-09","lastUpdate":"2024-10-09"},"enrollment":654,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis Eczema"],"interventions":[{"type":"DRUG","name":"Roflumilast Cream 0.15%","otherNames":["ARQ-151"]},{"type":"DRUG","name":"Vehicle Cream","otherNames":[]}],"arms":[{"label":"Roflumilast Cream 0.15%","type":"EXPERIMENTAL"},{"label":"Vehicle Cream","type":"PLACEBO_COMPARATOR"}],"summary":"This is a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) cream vs vehicle applied once daily (qd) for 4 weeks by participants with atopic dermatitis (eczema).","primaryOutcome":{"measure":"Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"Roflumilast Cream 0.15%","deltaMin":32,"sd":null},{"arm":"Vehicle Cream","deltaMin":15.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":49,"countries":["United States","Canada"]},"refs":{"pmids":["39292443"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":433},"commonTop":[]}}